Pharmacology: Don-A (Domperidone) is a dopamine receptor (D2) antagonist.
Don-A (Domperidone) is a selective peripheral dopamine antagonist at the D2 dopamine receptor in the Chemo-receptor Trigger Zone (CTZ) and stomach. Don-A (Domperidone) does not readily enter the central nervous system (the chemoreceptor trigger zone is considered to lie outside the blood brain barrier). Don-A (Domperidone) increases spontaneous gastric activity and antagonizes dopamine inhibition of gastric emptying. Don-A (Domperidone) has been shown to increase lower esophageal sphincter pressure and promotes esophageal and antral peristalsis and also increases pyloric dilatation. Don-A (Domperidone) increases the frequency, amplitude, duration of duodenal contraction and reduces the small bowel transit time. Don-A (Domperidone) has no acetylcholine like effect.
Don-A (Domperidone) is used as an antiemetic for the short-term treatment of nausea and vomiting of various aetiologies. It is also used for its prokinetic actions in dyspepsia and has been tried in diabetic gastroparesis.
Don-A (Domperidone) should be taken 15-30 minutes before a meal. The usual recommended oral dose is as follows:
Adult: 10-20 mL suspension every 6-8 hours.
Elderly: 10-20 mL suspension every 4-8 hours.
Children: 0.2-0.4 mg/kg body weight (2-4 mL suspension) every 4-8 hours.
OR AS DIRECTED BY THE PHYSICIAN.
There are no reported cases of overdosage.
Domperidone is contraindicated to patients having known hypersensitivity to this drug and in case of neonates. Domperidone should not be used when gastrointestinal stimulation might be dangerous i.e. gastrointestinal hemorrhage, obstruction, perforation or immediately after surgery.
Domperidone should be used with absolute caution in case of children because there may be an increased risk of extrapyramidal reactions in young children because of an incompletely developed blood brain barrier.
The safety of Domperidone has not been proven and it is, therefore, not recommended during pregnancy. Animal studies have not demonstrated teratogenic effect on the fetus. Domperidone may precipitate galactorrhea and improve postnatal lactation. It is secreted in breast milk but in very small quantities insufficient to be considered harmful.
Domperidone is not recommended for chronic use or for the routine prophylaxis of postoperative nausea and vomiting.
Extrapyramidal reactions are seen in 0.05% of patients in clinical studies. Domperidone may produce hyperprolactinemia (1.3%). This may result in galactorrhea, breast enlargement, soreness and reduced libido. Dry mouth (1.9%), thirst, headache (1.2%), nervousness, drowsiness (0.4%), diarrhea (0.2%), skin rash and itch (0.1%) may all follow treatment with Domperidone.
Domperidone may reduce the risk of hypoprolactinemic effect of bromocriptine. The action of Domperidone on GI function may be antagonized by antimuscarinics and opioid analgesics.
Store at temperatures not exceeding 30°C. Protect from light.
A03FA03 - domperidone ; Belongs to the class of propulsives. Used in the treatment of functional gastrointestinal disorders.